CompletedNot applicableNCT01383759

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Studying AL amyloidosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Hani Hassoun, MD
Memorial Sloan Kettering Cancer Center
Intervention
Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone(drug)
Enrollment
20 enrolled
Eligibility
18 years · All sexes
Timeline
2011 – 2019

Study locations (5)

Collaborators

Millennium Pharmaceuticals, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01383759 on ClinicalTrials.gov

Other trials for AL amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for AL amyloidosis →

← Back to all trials